Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Increase in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 8,509,923 shares, an increase of 234.4% from the April 15th total of 2,544,706 shares. Approximately 25.4% of the company’s stock are sold short. Based on an average daily volume of 79,730,843 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC raised its stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 212,087 shares of the company’s stock after acquiring an additional 183,878 shares during the period. Geode Capital Management LLC owned approximately 0.63% of Theriva Biologics worth $45,000 as of its most recent SEC filing. 6.17% of the stock is currently owned by institutional investors.

Theriva Biologics Stock Down 9.3%

Shares of NYSEAMERICAN TOVX traded down $0.03 during trading on Friday, reaching $0.29. The company had a trading volume of 2,596,802 shares, compared to its average volume of 45,280,248. Theriva Biologics has a 12-month low of $0.16 and a 12-month high of $0.86. The stock has a market cap of $9.82 million, a PE ratio of -0.01 and a beta of 1.17. The business’s 50-day moving average is $0.26 and its 200 day moving average is $0.24. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its earnings results on Tuesday, May 5th. The company reported ($0.05) EPS for the quarter.

Analyst Ratings Changes

Separately, Maxim Group raised Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $1.00.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.